Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Resverlogix Corp.

Market Cap 24.65M 17.63M 15.2M 13.99M 13.12M 1.67B 24.89M 165M 64.59M 816M 66.17M 64.77M 2.82B P/E Ratio 2024
-1.38x
P/E Ratio 2025 -2.68x
Enterprise Value 110M 79.01M 68.1M 62.67M 58.79M 7.47B 112M 741M 289M 3.66B 296M 290M 12.65B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.39%
Yield 2024 *
-
Yield 2025 -
1 day-5.00%
1 month-5.00%
3 months-20.83%
6 months-13.64%
Current year-5.00%
1 week 0.1
Extreme 0.095
0.1
1 month 0.08
Extreme 0.085
0.1
Current year 0.08
Extreme 0.085
0.14
1 year 0.04
Extreme 0.035
0.3
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.9
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap.
05-04Option

Chief Financial Officer

300,000 0.0949%
05-04Option

Chief Financial Officer

300,000 0.0949%
03-06Option

Chief Financial Officer

250,000 0.0869%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%0.00%+171.43%-13.64% 24.63M
-2.86%-0.63%+51.45%+109.01% 56.42B
-0.34%+2.91%+45.55%+46.87% 44.54B
+0.29%+3.09%-14.80%-18.16% 22.9B
-0.40%+3.44%-1.29%+405.24% 21.21B
-0.51%-5.56%+10.43%-29.97% 16.4B
-1.54%+0.66%+7.63%-40.19% 15.4B
-0.24%+0.57%+27.43%+182.22% 13.35B
+0.96%+6.56%+20.81% - 12.36B
+0.32%+1.60%+96.37%+207.56% 11.15B
Average -0.93%+1.49%+41.50%+94.33% 21.37B
Weighted average by Cap. -0.93%+2.54%+30.67%+99.58%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.46M -4.71M -4.33M -4.06M -516M -7.71M -51.22M -20.01M -253M -20.5M -20.06M -875M -7.77M -5.56M -4.79M -4.41M -4.13M -525M -7.84M -52.11M -20.35M -257M -20.85M -20.41M -890M
Net Debt 81.87M 58.57M 50.48M 46.46M 43.58M 5.54B 82.69M 549M 215M 2.71B 220M 215M 9.38B 85.79M 61.37M 52.9M 48.68M 45.67M 5.8B 86.65M 576M 225M 2.84B 230M 225M 9.83B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
15/06/26 0.0950 $ -5.00% 1,300
08/06/26 0.1000 $ +5.26% 13,000
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!